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Objective: The mechanism whereby the placental cells of a human immunodeficiency virus (HIV)-1-infected
mother protect the fetus from HIV-1 infection is unclear. Interferons (IFNs) inhibit the replication of viruses by
acting at various stages of the life cycle and may play a role in protecting against vertical transmission of HIV-1. In
addition the b-chemokines RANTES (regulated on activation T cell expressed and secreted), macrophage inflam-
matory protein-1-a (MIP-1a), and MIP-1b can block HIV-1 entry into cells by preventing the binding of the
macrophage-trophicHIV-1strainstothecoreceptorCCR5.Inthisstudythe productionofIFNsandb-chemokines
by placental trophoblasts of HIV-1-infected women who were HIV-1 non-transmitters was examined.
Methods: Placental trophoblastic cells were isolated from 29 HIV-1-infected and 10 control subjects. Super-
natants of trophoblast cultures were tested for the production of IFNs and b-chemokines by enzyme
linked immunosorbent assay (ELISA). Additionally, HIV-1-gag and IFN-b transcripts were determined by a
semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) assay.
Results: All placental trophoblasts of HIV-1-infected women contained HIV-1-gag transcripts. There were no
statistical differences in the median constitutive levels of IFN-a and IFN-g produced by trophoblasts of HIV-1-
infected and control subjects. In contrast, trophoblasts of HIV-1-infected women constitutively produced signifi-
cantly higher levels of IFN-b protein than trophoblasts of control subjects. Furthermore, the median levels of
b-chemokines produced by trophoblasts of HIV-infected and control women were similar.
Conclusions: Since there was nocorrelation between the placental HIV load andthe productionof interferonsor
b-chemokines, the role of trophoblast-derived IFNs and b-chemokines in protecting the fetus from infection with
HIV-1 is not clear.
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The mechanism by which HIV-1 infection is
transmitted from a mother to her infant is unclear
but may be related to a number of risk factors,
including preterm labor, the interval between
membrane rupture and delivery, and whether the
mother breastfeeds or is infected with a sexually-
transmitted disease during pregnancy1. At the
cellular level vertical transmission of HIV-1 may
occur as a result of an infected maternal cell cross-
ing from the maternal circulation into the fetal
circulation or by the direct transfer of the virus
from a maternal cell to a fetal cell2. For example, it
has been suggested that maternal macrophage-
trophic virus may serve as a vehicle to infect the
Infect Dis Obstet Gynecol 2001;9:95–104
Correspondence to: James M. Reuben, PhD, Department of Molecular Pathology, Division of Pathology and Laboratory
Medicine, Box 7, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
E-mail: jreuben@mdanderson.org
Clinical study 95fetus via infection of placental macrophages3,4.
Placental macrophages become infected with
HIV-1 through the CD4 receptor5,6 and the
CCR5 coreceptor7. However, thesusceptibility of
placental trophoblasts to infection with HIV-1 is
controversial: both successful2,4,8 and unsuccess-
ful9,10 infections have been reported. In support of
the former, we11 and others2,4,12,13 have found
HIV-1 provirus in macrophages and trophoblasts
and HIV-1-gag transcripts in the placental tropho-
blasts from women infected with HIV-114.
Nonetheless, the replication rate of HIV-1 in
trophoblastsis low15,16 and may notpermit dissem-
ination of the infection to other placental cells.
Immunological factors increasing the risk of
maternal-to-fetal HIV-1 transmission include
maternal immunosuppression17 and inflammation
of the placental membranes, mainly mediated by
cytokines18,19. Placental macrophages and tropho-
blasts constitutively secrete a variety of cytokines,
including granulocyte-macrophage colony stimu-
latingfactor,colony-stimulatingfactor,interleukin
(IL)-1b, IL-6, tumor necrosis factor-a (TNF-a),
interferons, and transforming growth factor20.
That some cytokines can up-regulate HIV-1
expression in T cells21 and in a promonocytic cell
line22 has been demonstrated and may provide a
mechanism through which fetal and maternal cells
latently infectedwithHIV-1 becomeactivated and
release productive virus. Thus, it is tempting to
speculate that the presence of inflammatory
cytokinesin theplacental microenvironment plays
a regulatory role in the expression of HIV-1. Even
so, the presence of HIV-1-infected cells in the
placenta and abnormal maternal immunologic
characteristics do not always lead to vertical trans-
mission14. While some workers believe that the
suboptimal permissiveness of trophoblasts for
HIV-1 replication may involve a restriction at the
level of HIV-1 integration13, others have specu-
lated that factors influencing viral gene trans-
cription and translation may be responsible23,24.
Throughout pregnancy interferons (IFNs) can be
detected in the maternal and fetal blood circula-
tions in response to intrauterine infection with
herpes simplex virus25, albeit sporadically and at
low concentration26.
Monocyte-macrophage tropic HIV-1 isolates
are non-syncytium inducing and are the
predominant isolates transmitted from mother to
fetus27–29. Placental macrophages express the CD4
receptor and the CCR3 and CCR5 chemokine
coreceptors7 that facilitate the entry of HIV-1 into
thecell.Placentaltrophoblastscanbeinfectedwith
HIV-1 even though they may express chemokine
receptors30, and not the CD4 receptor8,12,30–32.
Chemokinesontheotherhandmay preventinfec-
tion of maternal and fetal cells in the placenta by
preventing the binding of HIV-1 to the chemo-
kine receptors33,34 on the surface of the susceptible
cells. In this study the hypothesis that placental
HIV-1 load,asmeasured bythelevel ofHIV-1-gag
transcripts, is inversely correlated with thelevels of
IFNs and chemokines produced by the tropho-
blasts was tested.
SUBJECTS AND METHODS
Study population
Thirty-nine women, of whom 29 were HIV-1-
infected and ten were uninfected and healthy,
agreed to particpate in this study, which was
approved by the Institutional Research Board of
the hospitals affiliated with the Harris County
Hospital District in Houston, Texas. Accordingto
the census of the Texas Department of Health, the
racial and ethnic distribution of parturient women
in Harris County at the time of this study was 86%
African-American, 5% Hispanic, and 9% other
races. Among the 29 HIV-1-infected gravidas
from whom term placentas were obtained at
delivery, six were symptomatic for HIV-1 disease
throughout pregnancy. Five of the symptomatic
and 18 of the asymptomatic HIV-1-infected
women received zidovudine (ZDV), either intra-
partum or throughout pregnancy, or both
(Table 1). CD4 T-cell countswere available for 22
of the HIV-1-infected women. Blood samples
from 25 infants, including a set of twins, born to
HIV-1-infected women were obtained at birth, 1
month, 6 months, and 12 months of age. The
bloodwasassayed forthepresence ofHIV-1 infec-
tion by the co-culture method and/or for HIV-1
proviral DNA by the polymerase chain reaction
(PCR). Enumeration of peripheral CD4+ T-cell
countsofthese infantswas performed at birth.Five
infants were lost to follow-up.
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term deliveries performed bythesame obstetrician
who delivered the HIV patients. They were
selected based on term gestation, with no medical
complications of pregnancy or delivery. Delivery
was vaginal or by scheduled repeat Cesarean
section. The maternal ages of the control subjects
and the HIV patients were similar.
Isolation of placental trophoblastic cells
Trophoblastic cells were isolated from human
term placentas of 36–40 weeks’ gestation.
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Sample
number
Placental
HIV-1 level*
Mother’s status Infant’s status
ZDV** Symptom† CD4 count HIV-1†† CD4 count
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
H
H
H
H
L
H
H
L
H
L
L
L
L
L
L
H
H
H
L
H
H
L
H
H
H
L
L
H
H
y1
no
y1
no
y1,2
no
y
no
y
no
y1,2
y1,2
y1,2
y1,2
no
y
y
y
y1,2
y
y
y
y
y
y
y
y
y
y
N
Y
N
N
Y
N
N
N
N
N
N
N
N
Y
N
N
N
N
Y
N
Y
Y
N
N
N
N
N
N
N
195
na
537
na
na
814
411
284
499
201
390
126
364
na
160
336
na
330
403
362
174
na
327
819
212
123
na
10
50
Neg
Neg
Neg
LTFU
Neg
Neg
Neg
Neg
Neg
LTFU
Neg
Neg
Neg
Neg
LTFU
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
LTFU
Neg
Neg
LTFU
Neg
Neg
2861
722
4381
na
1987
4661
1728
1617/1802‡
3274
na
2683
2969
3126
2412
na
5316
2576
3337
2856
2941
2028
3444
4491
na
850
2351
na
3149
1736
*Levels of HIV-1-gag transcripts as determined by reverse transcription polymerase chain reaction (RT-PCR) (see Subjects and Methods):
L, low (<156 copies/mg of total RNA), H, high (>156 copies/mg total RNA); **zidovudine (ZDV) administered:y = yes, but details not
available; 1, ZDV administered throughout pregnancy; 2, ZDV administered intrapartum;
†Y = symptomatic, N = asymptomatic; na,
information not available;
††infant’s status: Neg, HIV-1 negative, LTFU, lost to follow-up;
‡a set of twins
Table 1 The level of HIV-1-gag transcripts in placental trophoblastic cells associated with the clinical characteristics
of human immunodeficiency virus (HIV)-1-infected mothers at delivery, and the infants’ status
Immediately after delivery rigorous isolation
procedures14,35–37 were employed to ensure the
purity of the trophoblast preparations. Cell
morphology and the production of human
chorionic gonadotropin were determined in
trophoblastic cell preparations using immuno-
cytochemical staining as previously reported14.
Cytospinpreparationsofthefinaltrophoblasticcell
fractions were stained with Wright–Giemsa
medium. The trophoblast preparations con-
sisted of a mixture of syncytiotrophoblasts
and cytotrophoblasts, with < 3% leukocyte
contamination.Production of interferons and b-chemokines by
trophoblasts
Two ml aliquots of trophoblastsat a concentration
of2 x106cells/mlin RPMI-1640medium supple-
mented with L-glutamine, 10% human AB
serum and antibiotics (200 U/ml penicillin and
200 mg/ml streptomycin) were placed in
12 mm ´ 75 mm tubes (Sigma Chemical Co.,
St.Louis,MO)andincubatedat 37°C inahumidi-
fied atmosphere with 5% CO2 for up to 48 h. At
12 h and24 htheculturetubeswere centrifugedat
450g for 10 min; the culture supernatants were
harvested and stored frozen at -20°C until assayed
for IFNs and b-chemokines. The levels of IFN-a,
IFN-g, macrophage inflammatory protein-1-a
(MIP-1a), MIP-1b, and RANTES (regulated on
activation T cell expressed and secreted) were
determined in supernatants of trophoblastic cell
cultures using QuantikineÔ ELISA kits (R & D
Systems,Minneapolis,MN).Thelevel ofIFN-bin
supernatants of trophoblastic cell cultures was
determined using the HuIFN-b1 ELISA kit
(Toray-Fuji Bionics Inc., Tokyo, Japan). All
measurements reported are the means of duplicate
sampling.
Reverse transcriptionof RNA into cDNA
Single-stranded cDNA in a final volume of 20 ml
was prepared by reverse transcription using (RT)
the GeneAmp RT-PCR kit (Applied Biosystems,
Foster City, CA). Briefly, after denaturation of
1 mg freshly prepared RNA at 68°C for 10 min, a
reaction mixture containing 2.5 mM random
hexamers, 1 mM dNTP, 5 mM MgCl2, 20 U
RNase inhibitor, and 50 U murine leukemia virus
(MuLV) reverse transcriptase was added to the
sample tube. The reaction was then allowed to
proceedat 42°Cfor60min,followedbyadditional
heatingat 95°Cfor5min toinactivatetheenzyme.
The resultant cDNA was either used immediately
or stored at -20°C.
Detection of HIV-1 RNA transcripts by RT-PCR
The cDNA synthesized from 1 mg total RNA iso-
lated from trophoblastic cells was used for PCR
amplification of HIV-1-gag sequences. To mini-
mize misprimed DNA amplification following
cDNA synthesis, the Hot Start PCR method was
used38. After AmpliWaxÔ (Applied Biosystems)
was added to tubes containing the cDNA, the
tubes were heated at 80°C for 5 min, and then
cooled down to 25°C for 5 min. The PCR master
mixture (0.2 mM primers SK38 and SK39,
0.2 mM dNTP,2 mM MgCl2, PCRBufferII,and
2.5 U AmpliTaq DNA polymerase) was prepared
using RT-PCR core reagents supplied by Applied
Biosystems, and aliquoted to each tube. The
sequencesfortheHIV-1-gagspecificprimersSK38
and SK39 (Applied Biosystems) are 5¢ATAATCC
ACCTATCCCAGTAGGAGAAAT3¢and 5¢TT
TGGTCCTTGTCTTATGTCCAGAATGC3¢,
respectively. After heating at 94°C for 5 min, the
PCR was carried out for 35 cycles of 30 s at 94°C,
30 s at 55°C and 30 s at 72°C and immediately
followed by a final extension at 72°C for 10 min
using a thermal cycler(Model 9600; Perkin-Elmer
Cetus, Norwalk, CT).
Two-fold serial dilutions, ranging from 5000
down to 156 copies, of HIV-1 positive control
DNA and HIV-1 negative control DNA (Applied
Biosystems) were also amplified by the PCR. The
specificity of the HIV-1-gag sequence was verified
byvacuumblottingthePCRproductontoanylon
membrane (GeneScreen Plus; DuPont, Boston,
MA), followed by hybridization with 32P-labeled
SK19 oligonucleotide (Applied Biosystems). The
SouthernblotoftheHIV-1-gagPCRproductswas
visualized using a PhosphoImager (Molecular
Dynamics, Sunnyvale, CA). Based on the signal
intensity of the band, each sample was arbitrarily
scored as having ‘low’ or ‘high’ copies of HIV-1-
gag transcripts if the pixal value of the sample band
was less than or greater than the number of
HIV-1-gag transcripts in the highest dilution for
the positive standard. Hence, samples with < 156
copieswerescoredas‘low’andsamples with> 156
copies were scored as ‘high’.
Detection of IFN-b and b-actin messages by
RT-PCR
One quarter of the cDNA derived from 1 mg of
total RNA was used for the PCR of IFN-b and
b-actin. The PCR mixture contained 0.125 mM
upstream and downstream primers, 0.2 mM
dNTP, 2 mM MgCl2, PCR Buffer II, and 2.5 U
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sequences for each of the PCR primers were as
follows: IFN-b sense primer, 5¢GAACTTTG
ACATCCCTGAGGAGATTAAGCAGC3¢;
IFN-b anti-sense primer, 5¢GTTCCTTAGGA-
TTTCCACTCTGACTATGGTCC3¢; b-actin
sense primer, 5¢CTGTCTGGCGGCACCAC-
CATG3¢; and b-actin anti-sense, 5¢CTCCTGC-
TTGCTGATCCAC3¢. The PCR products for
IFN-b and b-actin were 352 and 189 bp, respec-
tively. The IFN-b and b-actin was amplified for
35 cycles of denaturing at 94°C for 10 s, primer
annealing at 60°C for 20 s and extension at 72°C
for 20 s.
After PCR Southernblottingand hybridization
were performed.Thesignal intensities of thePCR
products of IFN-b and b-actin were obtained
using a phosphoimager. Using the signal intensity
of the b-actin band as a benchmark, the relative
intensity (in arbitrary units) of the IFN-b was
calculated and the results rendered as a ratio to the
b-actin amplification.
Statisticalanalysis
The nonparametric Mann–Whitney test was used
to determine differences intheproductionofIFNs
and b-chemokines and the level of IFN-b trans-
cription by placental trophoblasts of HIV-1-
infected and control women. The software
package PRISMÔ (GraphPad Software, Inc., San
Diego, CA) was used to perform the statistical
analyses.
RESULTS
Characteristics of study subjects
Twenty-five infants born to HIV-1-infected
mothershadclinical follow-upvisits forthree years
at the Pediatric AIDS Clinical Trials Unit in
Houstonand showed noevidence ofHIV-1 infec-
tion (Table 1). The HIV-1-gag sequence was
present in trophoblasts of all HIV-1-infected
women. Based on the semi-quantitative
RT-PCR, 12 of the 29 placental trophoblast
preparations from HIV-1 infected women had
< 156 copies of HIV-1-gag transcripts (Table 1).
Constitutivelevels of IFN-a, IFN-b, and IFN-g
produced by placental trophoblasts in culture
Constitutive levels of IFN-a, IFN-b, and IFN-g
were measured in culture supernatants of tropho-
blasts isolated from 29 HIV-1-infected and 9
control women. The median level of IFN-b
constitutively produced by trophoblasts of
HIV-1-infected women over a 24-h period was
significantly higher than that of control women
(Figure 1). The median constitutive levels of
IFN-b for HIV-1-infected compared with control
women were 3.5 pg/ml versus 3.1 pg/ml
(p = 0.0465) at 12 h and 3.7 pg/ml versus
3.1 pg/ml (p = 0.0293) at 24 h, respectively. On
the other hand, the median levels of IFN-g and
IFN-a constitutively produced by trophoblasts of
HIV-1-infected andcontrolwomenover the24-h
period were similar. The median constitutive
levels of IFN-a produced by the trophoblasts of
HIV-1-infected compared with control women
were 4.2 pg/ml versus 4.4 pg/ml at 12 h and
4.6 pg/ml versus 4.8 pg/ml at 24 h, respectively.
Similarly, the median constitutive levels of IFN-g
produced by the trophoblasts of HIV-1-infected
and control women over a 24-h period were
17.8 pg/ml and 14.4 pg/ml at 12 h compared with
17.8 pg/ml and 11.5 pg/ml at 24 h, respectively.
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Figure 1 Constitutive production of interferon-b by
placental trophoblasts at 12-h and 24-h cultures (solid
symbols: human immunodeficiency virus (HIV)-1-
infected; open symbols: controls). There were significant
differences in the median interferon (IFN)-b production
between trophoblasts of HIV-1-infected and control
women as determined by the Mann–Whitney test
(two-tailed); *p = 0.0465; **p = 0.0293 for 12-h and
24-h cultures, respectivelyThere was no correlation between the amounts of
interferons produced by trophoblasts and their
HIV-1 burden.
Transcription of IFN-b by placental trophoblasts
The level of IFN-b transcription was determined
by RT-PCR in trophoblasts obtained from 13
HIV-1-infected and 10 control women. The
median level of constitutive IFN-b transcription
(as theratio ofsignalintensity,IFN-b:b-actin) was
significantly higher in HIV-1-infected tropho-
blasts compared with that of control women at
12 h (0.6 vs 0.1, p = 0.0470)andat 24 h(0.9 vs 0.5,
p = 0.0386), respectively (Figure 2).
Production of b-chemokines by placental
trophoblasts
Constitutive levels of MIP-1a, MIP-1b, and
RANTES in culture supernatants of 17 HIV-1-
infectedand7controlsubjectswere determinedby
enzyme-linked immunosorbent assay (ELISA).
The medians of the constitutive levels of MIP-1a,
MIP-1b, and RANTES producedby trophoblasts
of HIV-1-infected women were 1025 pg/ml,
1236 pg/ml, and 160 pg/ml, respectively. The
medians of the constitutive levels of MIP-1a,
MIP-1b and RANTES produced by trophoblasts
of control women were 1628 pg/ml, 355 pg/ml,
and 359 pg/ml, respectively. Trophoblasts of
HIV-1-infected women constitutively produced
more MIP-1b and less MIP-1a and RANTES
compared with those of the control women
(Figure 3). However, there were no statistical
differences in the constitutive production of these
b-chemokines by trophoblasts of HIV-1-infected
and controlwomen.After24 h in culture,tropho-
blasts of HIV-1-infected and control women pro-
duced comparable levels of b-chemokines (data
notshown).Therewasnocorrelationbetweenthe
amounts of b-chemokines produced by tropho-
blasts and their HIV-1 burden.
DISCUSSION
Placental trophoblastic cells are epithelial cells of
fetal origin that closely resemble macrophages20
and,assuch,possessantiviral mechanismssimilar to
those of macrophages. For instance, infection of
monocytes/macrophages with HIV-1 leads to the
productionofIFN-b,atypeIIFNthatiscapableof
inhibiting replication of HIV-1 in these cells39.
However, infection of cells is not required for
the induction of IFNs as treatment of cultured
macrophages with a viral inducer such as HIV-1
rgp120 can lead to the predominant productionof
IFN-b by these cells39 and protection against sub-
sequent infection with the virus40.
The level of IFN-a production by placental
trophoblasts is dependent on the gestational age
and the stage of differentiation of these cells, with
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Figure 2 Constitutive transcription of interferon
(IFN)-b by placental trophoblasts (solid symbols: human
immunodeficiency virus (HIV)-1-infected; open symbols:
controls). There were significant differences in the
level of IFN-b transcription between trophoblasts of
HIV-1-infected and control women as determined
by the Mann–Whitney test (one-tailed); *p = 0.0470;
†p = 0.0386 for 12-h and 24-h cultures, respectively
Figure 3 Constitutive production of b-chemokines by
placental trophoblasts at 12-h cultures (solid symbols:
human immunodeficiency virus (HIV)-1-infected; open
symbols: controls). MIP, macrophage inflammatory pro-
tein; RANTES, regulated on activation T cell expressed
and secretedfirst trimester trophoblasts producing 5–6 times
more IFNs than third trimester trophoblasts41,42.
Among the IFNs produced locally by the placenta
during pregnancy43, IFN-b is the predominant
species and possesses more antiviral potential than
IFN-a40.Inthepresentstudy,trophoblastsisolated
from term placentas of HIV-1-infected and con-
trol women produced equivalent levels of IFN-a.
In contrast, trophoblasts from HIV-1-infected
women produced significantly more IFN-b than
trophoblasts of control women. The differential
expression of IFN-b and not IFN-a by HIV-1-
infected trophoblastsmay bedue,in part,to differ-
ences in transcriptional regulation, since the
promoter of IFN-b, and not the promoter of
IFN-a, contains an NF-kB binding site44. This
difference, along with the induction of NF-kB by
HIV-145,suggeststhatHIV-1 isa potentinducerof
IFN-b.
Alternatively, IFN-b transcription can be
inducedbyTNF-a46,acytokinepreviouslyshown
to be present at elevated levels in trophoblasts of
HIV-1-infected women14. Hence it is plausible
that HIV-1 together with the HIV-1-induced
TNF-a is capable of acting synergistically through
the multipoietic transcription factor NF-kB to
stimulate the production of IFN-b by HIV-1-
infected trophoblasts. On the other hand TNF-a
may directly or indirectly potentiate the antiviral
activity of a type II IFN, IFN-g, through the
induction of IFN-b46. Indeed, the major compo-
nent of the antiviral activity of IFN-g may be due
to its inductionofIFN-a and IFN-b47. Within the
placenta and throughout gestation, IFN-g is
produced by Hofbauer cells and syncytiotropho-
blasts48,49. IFN-g may protect the host cells from
infection with HIV-1 by inhibiting binding of the
virus with the coreceptor CCR5 on the target
cell50. As part of its role in immune activation,
IFN-ginduces2¢,5¢-oligoadenylate(2-5A)synthe-
tase activity to suppress HIV-1 replication in
trophoblasts51. Nevertheless, we detected equiva-
lentamountsofIFN-gproducedbytrophoblastsof
HIV-1-infected and control women and found
that there was no correlation between IFN-g
production and the HIV burden of placental
trophoblasts.
b-Chemokines can prevent cells from being
infected with HIV-1 by blocking the interaction
betweenthevirusand thechemokinereceptorson
the cells33,34. AlthoughRANTES and MIP-1a are
capableofbindingwithmore than onechemokine
receptor, MIP-1b can only bind with CCR552. A
previous study detected no RANTES and only
low levels of MIP-1a and MIP-1b in cultures of
early trophoblasts either infected or uninfected
with HIV-130. Not only were RANTES,
MIP-1a, and MIP-1b detected in cultures of term
trophoblasts from HIV-1-infected women in the
presentstudy,buthigherlevels ofMIP-1b,andnot
MIP-1a or RANTES, were produced by tropho-
blasts of HIV-1-infected women compared to
control women (1236 vs 355 pg/ml) (Figure 3).
The increase in MIP-1b productionalone by term
trophoblasts suggests that infection of the fetus
with HIV-1 may be prevented by blocking of
CCR5.
CONCLUSIONS
Despite the up-regulation in the transcription and
production of the inflammatory cytokines IL-1b,
IL-6, and TNF-a by trophoblasts of HIV-1-
infected women, in this study only a low level of
HIV-1 replication was detected in term tropho-
blasts14 which may be, in part, owing to the
combined antiviral activity of the three IFN
species47. It has been reported that only minute
amounts of these proteins are required to prevent
HIV-1 infection of target cells39. Alternatively,
reduction in virus burden in 23 of the 29
HIV-1-infected pregnant women may be due to
ZDV anti-retroviral therapy (Table 1). The exact
mechanism by which trophoblast IFNs defend the
fetus against infection with HIV-1 in the feto-
placental unit is unclear. Some workers have sug-
gested that IFNs can directly suppress HIV-1
replication39,40 throughtranscriptionalregulation44
and down-regulation of CD4 receptor expression
on susceptible cells50. However, the present study
was unable to demonstrate an inverse correlation
between the level of HIV-1-gag transcripts and the
production of interferons by placental tropho-
blasts. Although the production of b-chemokines
by trophoblasts of HIV-1-infected and control
women were similar, these chemokines may act
synergistically to controlthespread ofHIV-1 from
maternal to fetal cells at the local level. Further
HIV-1 in placental trophoblasts Lee et al.
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of IFNs and b-chemokines in preventing trans-
mission of HIV-1 from mother to fetus.
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